Approved Drug Products of Bristol Myers Squibb listed in the FDA Orange Book. Original Data : FDA Website

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Bristol-Myers Squibb is a differentiated company, led by our unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. We work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Each day, our employees around the world work together for patients – it drives everything we do. ...
Bristol-Myers Squibb is a differentiated company, led by our unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. We work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Each day, our employees around the world work together for patients – it drives everything we do. We are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
430 E. 29th Street, 14th Floor, New York, NY 10016
Telephone
Telephone
+1 (212) 546 4000

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

CPhI Worldwide, Milan

CPhI Worldwide, Milan

Not Confirmed

envelop Contact Supplier

CPhI Worldwide, Milan

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

INTERVIEW #SpeakPharma

[Sponsored by another company]
“We’re unlocking life-changing potential in complex molecules, without sacrificing time to market”
This week, SpeakPharma interviews Mike Riley, CEO of Veranova, a leading contract development and manufacturing organization (CDMO) confidently mastering complex APIs as it marks its second year as an independent company. Riley discusses Veranova’s key achievements, including a US$ 30 million investment in their Devens, Massachusetts (US) site to expand capabilities in antibody-drug conjugates (ADCs) and highly potent APIs (HPAPIs), and how it is navigating the increasing complexity of molecules. 🔑 HIGHLIGHTS// Veranova’s key achievements / navigating the increasing complexity of molecules Veranova is celebrating its second year as a stand-alone company. Can you share Veranova’s key milestones and achievements in its first two years? We have achieved incredible milestones over the last two years, thanks to the dedication and hard work of our team. Our first 12 months focused on establishing ourselves as an independent CDMO by building on the 50 years of expertise that we brought with us. In addition, we expanded our capabilities and applied a more agile approach available to us as a company singularly focused on life sciences. This has allowed us to move into our second year with clear and strategic goals for generating growth in our sites, people, capabilities, and offerings. Since being appointed as CEO in May 2023, I’ve had the pleasure of witnessing some exciting growth milestones of my own. Most recently, we announced an estimated US$ 30 million investment in our Devens, Massachusetts, site. This expansion will allow us to build upon existing development and manufacturing capabilities in ADCs and HPAPIs that will address the growing demand for strong US-based capacity in these key drug modalities. We also appointed our Advisory Board, thereby bolstering Veranova’s in-house expertise. Made up of four distinguished leaders in pharma and biopharma – including Dr. Carolyn Bertozzi, the 2022 Nobel Laureate in Chemistry – the Board has provided thought-leadership, guidance and expertise as we develop and execute our strategic growth and ideas. We were also proud to be recognized as one of the Society of Chemical Manufacturers and Affiliates’ 12 companies for industry-leading safety programs in 2023 and as a part of the Medicine Maker’s Power List in 2024. 🔑 HIGHLIGHTS// US$ 30 million investment in our Devens, Massachusetts, site / appointed our Advisory Board Molecules are becoming increasingly complex. Can you elaborate on how Veranova’s current capabilities are strategically designed to address this trend in the coming years? The pharmaceutical pipeline is witnessing an increasing number of complex and highly potent molecules. This trend is driven by the demand for more targeted, patient-centric therapeutics and the focus on innovative modalities such as ADCs and other bioconjugates. At Veranova, our expertise, world-class facilities, and scientific excellence enable us to provide our customers with the clarity and solutions needed to manage this development and manufacturing complexity and ultimately deliver the required treatments to customers and patients. Our people are key to this approach. We have an expert team ready to collaborate with customers at any point, from early development through large-scale commercial production. Our services include world-leading crystallization development, process development, and specialized manufacturing expertise for complex synthetic molecules, including those requiring chromatography capabilities. In many cases, we can provide all these under one roof. Our service offering to our customers is also based on the foundational element of strong quality and compliance systems. We operate multiple facilities approved by the US FDA, UK’s MHRA and other regulatory authorities and are continually focused on ways to strengthen our global quality management system. Looking ahead, we are focused on continually investing in our facilities and team to meet growing complexity, as evidenced by our recent announcement of new investment in our Devens site. This investment signals our commitment to providing state-of-the-art capacity and capabilities to enable these next-generation therapies to reach patients. It is a key milestone as we advance Veranova’s broader growth strategy. 🔑 HIGHLIGHTS// provide our customers with clarity and solutions / world-leading crystallization development / expertise for complex synthetic molecules / strong quality and compliance systems How is Veranova approaching the challenge of designing and manufacturing effective linker molecules for ADCs? As a leader in complex linker-payload synthesis, Veranova is committed to unlocking the life-changing potential of ADCs without letting their complexities slow down the development of much-needed cancer therapies. ADCs are intricate, multi-component molecules that require extensive expertise and agile collaboration to overcome unique development challenges. With over a decade of experience in ADC linker-payload systems, we have developed the ability to anticipate challenges and avoid common pitfalls. The ADC linker-payload components are complex structures that are difficult to crystallize and require specialized high-potent handling. Veranova’s differentiated combination of world-leading crystallization development capabilities, complex synthesis experience, chromatography expertise and high-potent-handling experience put us in a unique position to solve these challenges for customers and speed their products to the clinic. We prioritize getting it right the first time, minimizing change orders and ensuring high-quality results. We have developed a robust phase-appropriate strategy that is backed by state-of-the-art analytical equipment and regulatory procedures to ensure our partners can rapidly progress their ADC projects from pre-clinical to commercialization. 🔑 HIGHLIGHTS// unlocking the life-changing potential of ADCs / ensuring our partners can rapidly progress their ADC projects Can you specify how Veranova is using artificial intelligence (AI) to optimize manufacturing processes that can reduce costs and environmental footprint as well as speed up development? In May 2024, Veranova announced a partnership with Phorum.AI to leverage AI to optimize pharmaceutical manufacturing processes. This collaboration aims to enable the rapid development of processes that can drive efficiency and reduce costs while maximizing environmental sustainability. Our goal is to combine Veranova’s extensive empirical manufacturing dataset of owned APIs and drug master files with Phorum.AI’s computational chemistry engine in order to create a more powerful process-development tool for the benefit of Veranova’s and Phorum’s customers. At Veranova, we are constantly looking to employ innovative technologies and approaches to improve efficiency, accelerate time to market and reduce environmental footprint. We have the means to work with a variety of partners who have unique project requirements, without sacrificing time to market.  🔑 HIGHLIGHTS// partnership with Phorum.AI / create a more powerful process-development tool / improve efficiency, accelerate time to market and reduce environmental footprint

Impressions: 1659

https://www.pharmacompass.com/speak-pharma/we-re-unlocking-life-changing-potential-in-complex-molecules-without-sacrificing-time-to-market

#SpeakPharma With Veranova
10 Sep 2024

VLOG #PharmaReel

[Sponsored by another company]

DATA COMPILATION #PharmaFlow

[Sponsored by another company]
Excipient Market Overview: Roquette, Seqens, Evonik make strategic moves; new guidelines deal with contamination
The pharmaceutical industry has long recognized the critical role excipients or inactive ingredients play in drug formulation and delivery. Excipients can comprise up to 90 percent of a medicine's total ingredients and serve crucial functions as binders, disintegrants, coatings, preservatives, colors, and flavorings. According to recent market research, the pharmaceutical excipients market was valued at US$ 9.27 billion in 2023. It is growing at a compound annual growth rate (CAGR) of 7.03 percent and is projected to reach US$ 18.48 billion by 2032. The main factors driving market growth is an increased demand for multifunctional excipients, coupled with the expanding use of generic medications. The development in the biologics sector and advancements in nanotechnology are also contributing significantly to market growth. Major excipient providers include BASF, Evonik, Merck KGaA owned MilliporeSigma, Gangwal Healthcare, Roquette Frères, DuPont, Croda International, Seqens, Boai NKY Pharmaceuticals, PMC Isochem, Minakem, Kewpie Corporation, Ashland Global, SPI Pharma, Pfanstiehl, Nanjing Well Pharmaceutical, ICE Pharma, Anhui Ribobay Pharmaceutical and Nippon Fine Chemical.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available) WHO, India’s CDSCO tighten regulations; new GMP guidelines implemented to curb contamination Last year, the World Health Organization (WHO) issued a health alert linking at least 300 child deaths in the Gambia, Uzbekistan, and Indonesia to the ingestion of contaminated cough syrups containing unacceptable levels of diethylene glycol (DEG) and ethylene glycol (EG). In response to the tragic events, the WHO released two draft appendices to its guideline on good manufacturing practices (GMPs) for excipients this year. Manufacturers are now required to use suitable risk assessment tools to identify and mitigate potential hazards.  Since India-made cough syrups had been linked to the deaths, India’s drug regulator — Central Drugs Standard Control Organization (CDSCO) — took steps to prevent contamination, and advised drugmakers to only use pharmaceutical-grade excipients from approved sources. Furthermore, the Indian Health Ministry proposed amendments to the Drugs and Cosmetics Rules, 1945 to include details of excipients on drug labels. While listing all excipients on every strip of medicine may be challenging, the ministry suggested mentioning those causing hypersensitivity on the label. Applicants now mandatorily need to submit evidence of stability and safety of excipients. These regulatory developments have significant implications for excipient manufacturers and pharmaceutical companies worldwide. Leading pharmaceutical excipient firms like Gangwal Healthcare, Sigachi Industries, and Nitika Pharmaceuticals are well-positioned to meet these heightened quality and safety standards, given their long-standing commitment to producing high-quality, compliant excipients.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available)   Roquette buys IFF’s pharma unit for US$ 2.85 bn; Evonik opens new spray-drying facility in Darmstadt In a significant industry move, France-based Roquette entered into an agreement to acquire IFF's pharma solutions business in a deal valued at US$ 2.85 billion. This acquisition is set to rebalance family-owned Roquette’s portfolio around health and nutrition. The deal is expected to accelerate Roquette’s growth and significantly strengthen its presence in the excipients market. Evonik has opened a new facility for drying aqueous dispersions of its Eudragit polymers at its site in Darmstadt, Germany. The facility will help Evonik meet increasing demand from drugmakers for its oral drug delivery solutions. The plant uses green energy solutions. The company has also partnered University of Mainz to commercialize a new class of polyethylene glycols (PEG) lipids for nucleic acid delivery. Evonik’s Health Care business has been growing its nucleic acid drug and vaccine delivery portfolio.  Germany’s Johannes Gutenberg University of Mainz was the first to develop randomized polyethylene glycols (rPEGs). This collaboration aims to expand Evonik’s toolbox of technologies for nucleic acid-based medicines, offering an improved immunogenicity profile for lipid nanoparticle carriers used in mRNA vaccines and therapeutics. Asahi Kasei made significant strides in addressing a pressing industry concern that emerged in 2018 when potentially carcinogenic nitrosamine impurities were detected in several pharmaceuticals. Guided by regional authorities, such as the European Medicines Agency and the US Food and Drug Administration, the pharmaceutical industry has been carrying out extensive assessments and research to identify the cause of these impurities. In response to this challenge, Asahi Kasei developed its Ceolus microcrystalline cellulose with extremely low nitrite levels. The Japanese company achieved nitrite concentrations of 0.1 micrograms per gram or less, which is equivalent to 0.1 parts per million (ppm). The company also started full commercial operation of its second manufacturing facility for Ceolus in Japan, enhancing supply capacity and stability. JRS Pharma and Gujarat Microwax opened a state-of-the-art cotton-based croscarmellose sodium plant in Mehsana, Gujarat (India). This facility aims to produce high-quality excipients that meet global standards, potentially reducing India's dependency on imports and boosting its presence in the global excipient market. The Indian excipient industry accounts for less than 1 percent of the global market share.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available)   Seqens to advance innovative polymer; biologics, personalized medicine create demand for specialized excipients Recent industry collaborations highlight the ongoing innovation in novel excipients. France’s Seqens, with over 20 years of polymer development experience, was chosen by Pleryon Therapeutics to advance its leading osteoarthritis candidate – an innovative GMP polymer. This collaboration leverages Seqens’ newly expanded and modernized cGMP plant in Aramon, France, demonstrating the industry’s commitment to investing in advanced manufacturing capabilities for novel excipients.  The rise of biologics and personalized medicine has created a demand for specialized excipients capable of stabilizing complex molecules and enabling targeted drug delivery. Roquette’s launch of Lycagel Flex, a hydroxypropyl pemix for nutraceutical and pharmaceutical softgel capsules, exemplifies this trend. Built on Roquette’s market-first Lycagel pea starch technology, this plant-based alternative to gelatin offers manufacturers the flexibility to customize formulations for a range of production and end-user needs. The innovative pea starch foundation also underscores the industry’s move towards sustainable bio-based excipients. The trend towards patient-centric drug development has also influenced excipient innovation. Excipients that can improve palatability, ease of swallowing, or enable novel dosage forms (such as orally disintegrating tablets) are in high demand. For example, IFF brought a super disintegrant Ac-Di-Sol, that supports faster disintegration and drug dissolution in oral disintegrating tablets, improving patient experience.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available)   Our view The heightened regulatory scrutiny on excipients due to product contamination incidents has created a high risk perception and uncertainty around the regulatory acceptance of novel excipients. That said, novel excipients are central to the development of new drug modalities and therapies. Going forward, sustainability will also become an increasingly important factor in excipient selection and development. As the industry innovates towards biologics, personalized therapies, and patient-centric formulations, the role of high-quality, multifunctional excipients will only grow more vital in ensuring drug stability, bioavailability, and patient compliance. Companies that can navigate the complex regulatory landscape, invest in R&D, and offer high-quality, multifunctional excipients will be well-positioned to succeed in this evolving market.   

Impressions: 727

https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-seqens-evonik-make-strategic-moves-new-guidelines-deal-with-contamination

#PharmaFlow by PHARMACOMPASS
12 Sep 2024

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20240914166580/en

BUSINESSWIRE
15 Sep 2024

https://www.fiercepharma.com/pharma/gsk-zejula-misses-survival-goal-first-line-ovarian-cancer-pharma-rubraca-opdivo-combo

FIERCE PHARMA
14 Sep 2024

https://endpts.com/pantera-raises-e93m-to-radically-improve-supply-of-actinium-for-radiotherapeutics/

ENDPTS
12 Sep 2024

https://www.businesswire.com/news/home/20240912717463/en

BUSINESSWIRE
12 Sep 2024

https://www.fiercepharma.com/marketing/bristol-myers-squibb-staffers-start-pedaling-against-cancer-3000-mile-fundraising-push

FIERCE PHARMA
09 Sep 2024

https://www.reuters.com/markets/deals/bristol-myers-squibb-backed-zenas-biopharma-seeks-up-6897-mln-valuation-us-ipo-2024-09-06/

REUTERS
06 Sep 2024

Excipients

Click here to find the perfect excipient manufacturers by their capabilities

Inspections and registrations

Upload your audits for free, ask us

ABOUT THIS PAGE

Contact Bristol Myers Squibb and get a quotation

Bristol Myers Squibb is a supplier offers 89 products (APIs, Excipients or Intermediates).

Find a price of Tremelimumab bulk with DMF offered by Bristol Myers Squibb

Find a price of 6-Aminopenicillanic Acid bulk offered by Bristol Myers Squibb

Find a price of 7-Amino Cephalosporanic Acid bulk offered by Bristol Myers Squibb

Find a price of 7-Aminodesacetoxycephalosporanic Acid bulk offered by Bristol Myers Squibb

Find a price of Amikacin bulk offered by Bristol Myers Squibb

Find a price of Amikacin Sulfate bulk offered by Bristol Myers Squibb

Find a price of Amoxicillin Trihydrate bulk offered by Bristol Myers Squibb

Find a price of Amphotericin B bulk offered by Bristol Myers Squibb

Find a price of Ampicillin bulk offered by Bristol Myers Squibb

Find a price of Ampicillin Sodium bulk offered by Bristol Myers Squibb

Find a price of Ampicillin Trihydrate bulk offered by Bristol Myers Squibb

Find a price of Aripiprazole bulk offered by Bristol Myers Squibb

Find a price of Benzylpenicillin Sodium bulk offered by Bristol Myers Squibb

Find a price of Calcium Amphomycin bulk offered by Bristol Myers Squibb

Find a price of Carmustine bulk offered by Bristol Myers Squibb

Find a price of Cefaclor bulk offered by Bristol Myers Squibb

Find a price of Cefadroxil bulk offered by Bristol Myers Squibb

Find a price of Cefazolin Sodium bulk offered by Bristol Myers Squibb

Find a price of Cephalexin bulk offered by Bristol Myers Squibb

Find a price of Cephapirin Sodium bulk offered by Bristol Myers Squibb

Find a price of Cephradine bulk offered by Bristol Myers Squibb

Find a price of Cloxacillin Sodium bulk offered by Bristol Myers Squibb

Find a price of Desonide bulk offered by Bristol Myers Squibb

Find a price of Diethylstilbestrol bulk offered by Bristol Myers Squibb

Find a price of Dimetridazol bulk offered by Bristol Myers Squibb

Find a price of Enoxacin bulk offered by Bristol Myers Squibb

Find a price of Fluphenazine bulk offered by Bristol Myers Squibb

Find a price of Fluphenazine Decanoate bulk offered by Bristol Myers Squibb

Find a price of Glucosamine Hydrochloride bulk offered by Bristol Myers Squibb

Find a price of Halcinonide bulk offered by Bristol Myers Squibb

Find a price of Hetacillin bulk offered by Bristol Myers Squibb

Find a price of Hetacillin Potassium bulk offered by Bristol Myers Squibb

Find a price of Hydroxyurea bulk offered by Bristol Myers Squibb

Find a price of Insulin bulk offered by Bristol Myers Squibb

Find a price of Irbesartan bulk offered by Bristol Myers Squibb

Find a price of Isoniazid bulk offered by Bristol Myers Squibb

Find a price of Kanamycin Sulfate bulk offered by Bristol Myers Squibb

Find a price of Methicillin bulk offered by Bristol Myers Squibb

Find a price of Nystatin bulk offered by Bristol Myers Squibb

Find a price of Oxacillin Sodium bulk offered by Bristol Myers Squibb

Find a price of Penicillin G Potassium bulk offered by Bristol Myers Squibb

Find a price of Penicillin V Potassium bulk offered by Bristol Myers Squibb

Find a price of Pentamidine Isethionate bulk offered by Bristol Myers Squibb

Find a price of Piperacillin Sodium bulk offered by Bristol Myers Squibb

Find a price of Piperazine bulk offered by Bristol Myers Squibb

Find a price of Sodium Dicloxacillin bulk offered by Bristol Myers Squibb

Find a price of Tetracycline Hydrochloride bulk offered by Bristol Myers Squibb

Find a price of Tipredane bulk offered by Bristol Myers Squibb

Find a price of Triamcinolone Acetonide bulk offered by Bristol Myers Squibb

Find a price of Triamcinolone Diacetate bulk offered by Bristol Myers Squibb

Find a price of Triamcinolone Hexacetonide bulk offered by Bristol Myers Squibb

Find a price of Triflupromazine bulk offered by Bristol Myers Squibb

Find a price of Vitamin B12 bulk offered by Bristol Myers Squibb

Find a price of Warfarin Sodium bulk offered by Bristol Myers Squibb

Find a price of PICCOLITE RESIN S 115 L bulk offered by Bristol Myers Squibb

Find a price of BIS (2-HYDROXY-5-CHLORO PHENYL) SULFIDE bulk offered by Bristol Myers Squibb

Find a price of COMPOUND SQ 21, 286 bulk offered by Bristol Myers Squibb

Find a price of TESTING FACILITIES FOR RAW MATERIALS & FINISHED GOODS bulk offered by Bristol Myers Squibb

Find a price of HUMAN MONOCLONAL ANTIBODY (MDX-214) TO THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) bulk offered by Bristol Myers Squibb

Find a price of FACILITIES FOR THE MFG. OF SEMISOLIDS IN HUMACAO, PUERTO RICO bulk offered by Bristol Myers Squibb

Find a price of MURINE MONOCLONAL ANTIBODY (ALPHA CTLA4) TOCTLA4 bulk offered by Bristol Myers Squibb

Find a price of FACILITIES LOCATED IN MAYAGUEZ, PUERTO RICO bulk offered by Bristol Myers Squibb

Find a price of MANUFACTURE OF HYDROXYUREA bulk offered by Bristol Myers Squibb

Find a price of MDX-1303 VALORTIM (TM), ANTI-BACILLUS ANTHRACIS PROTECTIVE ANTIGEN HUMAN MONOCLONAL ANTIBODY bulk offered by Bristol Myers Squibb

Find a price of PROLIXIN ELIXIR (FLUPHENAZINE HYDROCHLORIDE) bulk offered by Bristol Myers Squibb

Find a price of JM-9 FOR INJECTION bulk offered by Bristol Myers Squibb

Find a price of HYDROCHLORIDE 6484 R.P. (VET MED) bulk offered by Bristol Myers Squibb

Find a price of PLASTIC CONTAINERS bulk offered by Bristol Myers Squibb

Find a price of SUMMARIES OF THE BACKGROUND & QUALIFICATION OF INVEST & MONITORS bulk offered by Bristol Myers Squibb

Find a price of DROCINONIDE PHOSPHATE POTASSIUM bulk offered by Bristol Myers Squibb

Find a price of HUMAN MONOCLONAL ANTIBODY (MDX-070) TO PROSTATE SPECIFIC MEMBRANE ANTIGEN bulk offered by Bristol Myers Squibb

Find a price of TRI-BUFFERED BUFFERIN bulk offered by Bristol Myers Squibb

Find a price of POT. MELARSONYL-mel W (TRIMELARSAN)-MFG, SPECS, & METH. OF ANALYSIS bulk offered by Bristol Myers Squibb

Find a price of METHODS, FACILITIES, AND CONTROLS IN MAYAGUEZ, PUERTO RICO bulk offered by Bristol Myers Squibb

Find a price of RICIN CONJUGATED MURINE MONOCLONAL ANTIBODY (MDX-RA) TO HUMAN LENS EPITHELIAL CELLS bulk offered by Bristol Myers Squibb

Find a price of LISTING OF INDS bulk offered by Bristol Myers Squibb

Find a price of MDX-1100 (ANTI-CXCL 10/ANTI-IP-10 HUMAN MONOCLONAL ANTIBODY) bulk offered by Bristol Myers Squibb

Find a price of MDX-015 (ANTI-IL15 HUMAN MONOCLONAL ANTIBODY) bulk offered by Bristol Myers Squibb

Find a price of PERSONNEL FOR PUERTO RICO PLANTS bulk offered by Bristol Myers Squibb

Find a price of FORMULAS: RHODIAL & BOUQUET 5886 bulk offered by Bristol Myers Squibb

Find a price of HUMAN MONOCLONAL ANTIBODY (MDX-067) TO HEPARANASE bulk offered by Bristol Myers Squibb

Find a price of FACILITIES AND CONTROLS PERSONNEL FOR MANUFACTURE AND CONTROL bulk offered by Bristol Myers Squibb

Find a price of HUMAN MONOCLONAL ANTIBODY (MDX-060) TO CD30 bulk offered by Bristol Myers Squibb

Find a price of FACILITIES LOCATED IN BARCELONETA, PUERTO RICO - PREVIOUSLY AN ANTIBIOTIC FILE bulk offered by Bristol Myers Squibb

Find a price of MFG. ANALYTICAL SPECS. & METHODS OF ANALYSIS FOR MEL B (ARSOBAL) bulk offered by Bristol Myers Squibb

Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES. bulk offered by Bristol Myers Squibb

Find a price of MURINE MONOCLONAL ANTIBODY (PM-81) TO HUMAN MYELOID DIFFERENTIATION ANTIGEN bulk offered by Bristol Myers Squibb

Find a price of TESTOLACTONE TABLETS, 250 MG bulk offered by Bristol Myers Squibb

Find a price of PATIENT STARTER PACKAGES bulk offered by Bristol Myers Squibb

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty